In contrast, the pan-ERBB inhibitor, afatinib, can block this compensatory mechanism and stably inhibit KRAS activity, thereby reducing the growth of KRAS-mutated NSCLC cells in preclinical models [150]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.